Special Report: ASX-listed health, nutrition and wellness company, EVE Investments, has launched its probiotic bio-fermented honey drink in Australia as the US and Japan wait in the wings.

Capitalising on a groundswell for diversified health products in China, EVE Investments (ASX:EVE) continues to drive momentum forward after signalling plans to expand its premium consumer branded range with a probiotic bio-fermented honey drink by its subsidiary, Meluka Australia.

After securing an order for over 57,000 units of its Meluka tea tree oil products for China, Meluka Australia has launched its Raw Probiotic Concentrate drink with Native Honey and Lemon.

This marks the first product of its kind in the collection, with subsequent launches slated for the US (via Amazon) and Japan in the coming months.

According to figures from Transparency Market Research, global estimated revenue generated by the fermented non-dairy and non-alcoholic beverages market reached $US1.9bn ($3.2bn) last year as consumers sought out natural, low sugar and low alcohol beverage alternatives to artificially carbonated drinks.

Meluka Australia CEO Ben Rohr told Stockhead that as one of Australia’s leading raw honey and tea tree oil producers, Meluka Australia was in a robust position to be able to provide health-conscious consumers products they could trust with the launch of the new range.

“The rising awareness among everyday consumers of the overall importance of gut health and microbiome diversity means product manufacturers can no longer afford to stand still as people seek healthier alternatives to traditional drinks,” he said.

“Meluka Australia is entering the market at an exciting time as we look to offer a fresh new product that we know Australians will love.”

Containing native honey produced in the Bungawalbin Valley in Northern NSW, the Meluka Australia offering is EVE’s first bio-fermented honey drink and places the company in a strong position as Australia’s leading, locally owned premium honey and tea tree oil producer.

EVE, who raised $9.2m following the completion of a successful share subscription in January, is well capitalised to build on a sustained period of growth as it looks to fund its ambitious expansion plans and marketing initiatives across Australia, Asia Pacific and North America.

Managing director Bill Fry said he was pleased with the tremendous momentum the company was gaining in key lucrative markets for expansion like China and the US.

“EVE continues to go from strength to strength and we are proud to have been able to deliver on our promise to give consumers the access to quality new products like our premium bio-fermented honey range as well as our organic tea tree oil products” Fry told Stockhead.

But he said the company refused to rest on its laurels as it aggressively targets growth and new commercial opportunities.

 

“This is only the beginning for Meluka Australia. With further launches planned for our bio-fermented honey range next month, EVE is already hitting its stride and we’re really excited to bring our growth strategy to fruition.”

This story was developed in collaboration with EVE Investments, a Stockhead advertiser at the time of publishing.
This story does not constitute financial product advice. You should consider obtaining independent advice before making any financial decisions.

Read MoreHealth

Featured Companies

You might be interested in